Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
20 avr. 2022 07h30 HE
|
Otonomy, Inc.
Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability...
Decibel Therapeutics to Participate in Upcoming Investor Conferences
22 mars 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
18 mars 2022 07h00 HE
|
Decibel Therapeutics, Inc.
- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research...
As the US Gets Closer to Over-the-Counter Hearing Aids, Experts Urge Consumers to See a Hearing Care Professional First
03 mars 2022 10h11 HE
|
Hearing Industries Association
Washington, D.C., March 03, 2022 (GLOBE NEWSWIRE) -- In recognition of World Hearing Day on March 3, the Hearing Industries Association (HIA) is releasing results of a recent survey of 1,000 adults...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
28 févr. 2022 16h27 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy to Participate in Two Upcoming Investor Conferences
28 févr. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
25 févr. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
17 févr. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
16 févr. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two...
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 16h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...